Analgesics
Antiandrogens
Antihistamines
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchCannabidiolCannabidiol (more..)
Metformin Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta Thermotherapy Meta
Melatonin Meta

All Studies   Meta Analysis       

Cannabidiol and Its Effects on Patients with COVID-19 Infection

Kuntzman et al., Israel Medical Association Journal, 27:2
Feb 2025  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 77% Improvement Relative Risk ICU admission 57% Hospitalization time 22% Cannabidiol  Kuntzman et al.  LATE TREATMENT  DB RCT Is late treatment with cannabidiol beneficial for COVID-19? Double-blind RCT 10 patients in Israel Lower mortality with cannabidiol (not stat. sig., p=0.3) c19early.org Kuntzman et al., Israel Medical Associ.., Feb 2025 Favorscannabidiol Favorscontrol 0 0.5 1 1.5 2+
RCT 10 hospitalized COVID-19 patients showing potential benefit with sublingual cannabidiol (CBD) oil. There was only 7 patients in the treatment arm and 3 in the placebo group. CBD-treated patients showed a trends toward lower inflammatory cytokine levels including IL-6, IL-10, TNF-α, and C-reactive protein, though none reached statistical significance.
risk of death, 76.9% lower, RR 0.23, p = 0.30, treatment 0 of 7 (0.0%), control 1 of 3 (33.3%), NNT 3.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of ICU admission, 57.1% lower, RR 0.43, p = 1.00, treatment 1 of 7 (14.3%), control 1 of 3 (33.3%), NNT 5.2.
hospitalization time, 22.4% lower, relative time 0.78, p = 0.61, treatment mean 5.9 (±5.13) n=7, control mean 7.6 (±3.0) n=3.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kuntzman et al., 28 Feb 2025, Double Blind Randomized Controlled Trial, Israel, peer-reviewed, 3 authors.
This PaperCannabidiolAll
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit